Home / Pipeline / STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% Products STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% Phase 3 Completed ⚡ Active Interest: 40/100
Open Angle Glaucoma, Ocular Hypertension
Open Angle Glaucoma, Ocular Hypertension
Aug 8, 2022 → Jan 30, 2024
About STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5% is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma, Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05503901. Target conditions include Open Angle Glaucoma, Ocular Hypertension.
What happened to similar drugs? 20 of 20 similar drugs in Open Angle Glaucoma, Ocular Hypertension were approved
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT05503901 Phase 3 Completed Aug 8, 2022 Jan 30, 2024 Open Angle Glaucoma, Ocular Hypertension
Competing Products 20 competing products in Open Angle Glaucoma, Ocular Hypertension
See all competitors Product Company Stage Hype Score Ilofotase alfa + Placebo AM-Pharma Phase 2 Test - Bimatoprost 0.01% Ophthalmic Solution + Reference - LUMIGAN® (Bimatoprost 0.01% Ophthalmic Solution) Mankind Pharma Phase 3 Latanoprost plus adjunctive glaucoma medication Sight Sciences Approved Pirtobrutinib + Placebo Eli Lilly Phase 1/2 Anti-(integrin beta-3) human monoclonal antibody Rallybio Phase 2 SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 Ophthalmic Emulsion, Placebo Skye Bioscience Phase 2 Micafungin Astellas Pharma Approved SDP-133 + Lumigan Sun Pharmaceutical Phase 3 Brinzolamide ophthalmic suspension + Azopt® Sun Pharmaceutical Phase 3 Placebo + Lusutrombopag Shionogi Phase 2 Lusutrombopag Shionogi Phase 2 Avatrombopag + Avatrombopag + Placebo Eisai Phase 2 E5501 Eisai Phase 1 avatrombopag Eisai Phase 1 E5501 + Drug: E5501 Eisai Phase 1 E5501 40 mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food + E5501 40mg 2 x 20-mg tablets, orally, fasted + E5501 40 mg 2 x 20-mg tablets, orally, with food Eisai Phase 1 Eltrombopag + Avatrombopag + Standard of care Eisai Phase 3 Placebo + Avatrombopag tablets Eisai Phase 2 avatrombopag (lower baseline platelet count) + placebo (lower baseline platelet count) + avatrombopag (higher baseline platelet count) + placebo (higher baseline platelet count) Eisai Phase 3 avatrombopag + Placebo Eisai Phase 2